| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| M SILDENAFIL (is an active metabolite)
| SILDENAFIL | GENITO | - | PHOSPHODIESTERASE TYPE 5 (PDE5) | cGMP-specific 3,5-cyclic phosphodiesterase UNIPROT O76074 PDE5A more at DrugCentral | EMA | ||||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| SILDENAFIL (has an active metabolite)
| SILDENAFIL | GENITO | ORAL INTRAVENOUS | F 41 PERCENT VD 105 LITER PPB 96 PERCENT Cl 18 LITER / HOUR (EQN) HT 4 HOUR SOLUBILITY 3.5 MILLIGRAM / MILLILITER | PHOSPHODIESTERASE TYPE 5 (PDE5) | cGMP-specific 3,5-cyclic phosphodiesterase UNIPROT O76074 PDE5A more at DrugCentral | EMA | |||
